High Failure Rate of Noninvasive Oxygenation Strategies in Critically Ill Subjects With Acute Hypoxemic Respiratory Failure Due to COVID-19
Overview
Authors
Affiliations
Background: The efficacy of noninvasive oxygenation strategies (NIOS) in treating COVID-19 disease is unknown. We conducted a prospective observational study to assess the rate of NIOS failure in subjects treated in the ICU for hypoxemic respiratory failure due to COVID-19.
Methods: Patients receiving first-line treatment NIOS for hypoxemic respiratory failure due to COVID-19 in the ICU of a university hospital were included in this study; laboratory data were collected upon arrival, and 28-d outcome was recorded. After propensity score matching based on Simplified Acute Physiology (SAPS) II score, age, [Formula: see text] and [Formula: see text] at arrival, the NIOS failure rate in subjects with COVID-19 was compared to a previously published cohort who received NIOS during hypoxemic respiratory failure due to other causes.
Results: A total of 85 subjects received first-line treatment with NIOS. The most frequently used methods were helmet noninvasive ventilation and high-flow nasal cannula; of these, 52 subjects (61%) required endotracheal intubation. Independent factors associated with NIOS failure were SAPS II score ( = .009) and serum lactate dehydrogenase at enrollment ( = .02); the combination of SAPS II score ≥ 33 with serum lactate dehydrogenase ≥ 405 units/L at ICU admission had 91% specificity in predicting the need for endotracheal intubation. In the propensity-matched cohorts (54 pairs), subjects with COVID-19 showed higher risk of NIOS failure than those with other causes of hypoxemic respiratory failure (59% vs 35%, = .02), with an adjusted hazard ratio of 2 (95% CI 1.1-3.6, = .01).
Conclusions: As compared to hypoxemic respiratory failure due to other etiologies, subjects with COVID-19 who were treated with NIOS in the ICU were burdened by a 2-fold higher risk of failure. Subjects with a SAPS II score ≥ 33 and serum lactate dehydrogenase ≥ 405 units/L represent the population with the greatest risk.
How to use facemask noninvasive ventilation.
Ferreyro B, De Jong A, Grieco D Intensive Care Med. 2024; 50(8):1346-1349.
PMID: 38801519 DOI: 10.1007/s00134-024-07471-y.
da Cruz A, Martins G, Martins C, Marques V, Christovam S, Battaglini D Eur J Med Res. 2024; 29(1):248.
PMID: 38649940 PMC: 11036698. DOI: 10.1186/s40001-024-01826-3.
Fisher J, Subbian V, Essay P, Pungitore S, Bedrick E, Mosier J CHEST Crit Care. 2024; 2(1).
PMID: 38645483 PMC: 11027508. DOI: 10.1016/j.chstcc.2023.100030.
Tetaj N, De Pascale G, Antonelli M, Vargas J, Savino M, Pugliese F J Clin Med. 2024; 13(6).
PMID: 38541932 PMC: 10971014. DOI: 10.3390/jcm13061707.
Mosier J, Tidswell M, Wang H J Am Coll Emerg Physicians Open. 2024; 5(2):e13118.
PMID: 38464331 PMC: 10920951. DOI: 10.1002/emp2.13118.